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Autoimmune diseases (AIDs) have been associated with accelerated atherosclerosis (AT) leading to increased cardio- and
cerebrovascular disease risk. Traditional risk factors, as well as systemic inﬂammation mediators, including cytokines, chemokines,
proteases, autoantibodies, adhesion receptors, and others, have been implicated in the development of these vascular pathologies.
Yet, the characteristics of vasculopathies may signiﬁcantly diﬀer depending on the underlying disease. In recent years, many
new genes and signalling pathways involved in autoimmunity with often overlapping patterns between diﬀerent disease entities
have been further detected. Epigenetics, the control of gene packaging and expression independent of alterations in the DNA
sequence, is providing new directions linking genetics and environmental factors. Epigenetic regulatory mechanisms comprise
DNA methylation, histone modiﬁcations, and microRNA activity, all of which act upon gene and protein expression levels. Recent
ﬁndings have contributed to our understanding of how epigenetic modiﬁcations could inﬂuence AID development, not only
showing diﬀerences between AID patients and healthy controls, but also showing how one disease diﬀers from another and even
how the expression of key proteins involved in the development of each disease is regulated.
1.Introduction
Autoimmunediseasesareaheterogeneousgroupofdisorders
characterised by humoral, cell-mediated immune responses
against various self-constituents. It is widely known that
AIDs are the result of interaction between predispos-
ing genetic factors, deregulation of the immune system,
and environmental triggering factors [1]. Several systemic
autoimmune conditions, including rheumatoid arthritis
(RA),systemiclupuserythematosus(SLE),antiphospholipid
syndrome (APS), and primary Sj¨ ogren Syndrome (pSS) are
linked to enhanced atherosclerosis, and consequently higher
cardiovascular morbidity and mortality rates. The devel-
opment of cardiovascular disease involves genetic factors
as well as other acquired and modiﬁable risk factors (e.g.,
hypercholesterolemia, diabetes mellitus, and hypertension).
Inﬂammatory components of the immune response, as well
as autoimmune elements (e.g., autoantibodies, autoantigens,
and autoreactive lymphocytes), seem to be also involved in
these processes [2–6].
From the genetic standpoint, it is known that in the
case of AID there is a complex interaction between the
product of various genes, and genomic high-throughput
analyses can tell us which genes are turned on or oﬀ
in diﬀerent tissues from patients with autoimmune dis-
eases. Recent genomic and transcriptomic proﬁling stud-
ies have implicated certain cytokines, surface receptors,
signalling pathways, and cell types in the pathogenesis
of inﬂammatory diseases [7–17]. This paper is focused
in epigenomic approaches used to deep into the origin2 Clinical and Developmental Immunology
of the mechanisms associated with both disease develop-
ment and vascular involvement in systemic autoimmune
diseases.
2.EpigeneticMechanisms in
Autoimmune Diseases
Systemic autoimmune diseases (AIDs) are of complex aeti-
ology, characterised by an intricate interplay of various
factors. A myriad of genes lies behind the heterogeneous
manifestations of these diseases, and the overexpression and
repression of particular genes form a speciﬁc gene expression
proﬁle (GEP) (genetic ﬁngerprints) that is characteristic to
thegivendiseasephenotype.Pathophysiologicalmechanisms
thatmightconnectatherosclerosisandcardiovasculardisease
with SLE and RA have been greatly broadened with the
application of genomic technologies, which have allowed
explaining how these alterations might be associated to
each AID [7–10, 12, 13]. One important and emerging
mechanism controlling gene expression is epigenetics.
Epigenetics,thecontrolofgenepackagingandexpression
independentofalterationsintheDNAsequence,isproviding
new directions linking genomics and environmental factors.
The epigenetic process is important for controlling patterns
of gene expression during the cell cycle, development, and
in response to environmental or biological modiﬁcations.
Moreover, epigenetic changes may be reversed [18].
A remarkable example of disease in which epigenetic
abnormalities and patterns of inheritance are extremely
complex is SLE. The high incidence of twin pairs in which
SLE develops in only one of the siblings supports the
notion that environmental factors and their involvement in
epigenetic modiﬁcations could aﬀect the onset of disease.
In the last year, several new ﬁndings about epigenetic
modiﬁcations of gene expression were reported in dif-
ferent AIDs. These modiﬁcations describe changes in the
expression of DNA that result from methylation, post-
translational modiﬁcations of the histone proteins, includ-
ing acetylation/deacetylation, methylation, and microRNAs
(Figures 1 and 2). Most interestingly, these modiﬁcations
seem to act in concert [19].
2.1. Histone Modiﬁcations. Histone modiﬁcations are regu-
lated during the cell cycle, cellular development, and diﬀer-
entiation [20]. The two main histone modiﬁcations, histone
acetylation and histone methylation, are tightly controlled.
Indeed, histone acetylation is counterbalanced by histone
deacetylation: histone acetyl transferase (HAT) adds the
acetyl group, and the histone deacetylases (HDAC) remove
it. HATs and HDACs reciprocally regulate the acetylation
status of cellular proteins. Acetylation of histones promotes
unwinding of compacted chromatin and allows access
of transcription factors to gene promoter regions, while
deacetylation of terminal lysine residues contributes to the
silencing of transcription. Changes in relative HAT/HDAC
activity would inﬂuence the sensitivity of cellular gene
transcription in response to extracellular stimuli.
Similarly, the impact of lysine or arginine methylation by
histone methyltransferases (HMTs) is reversed by demethy-
lating enzymes, such as lysine-speciﬁc demethylase (LSD)1
and JmjC domain-containing histone demethylase (JMJC).
Global H3 and H4 hypoacetylation and hypermethy-
lation characterize CD4+ T cells from SLE patients [21].
Moreover, a very recent study has demonstrated that there
are signiﬁcant clusters of aberrantly expressed genes in SLE
(includingthosecodifyingforasetofchemokines)whichare
strongly associated with altered H4 acetylation [22].
2.2. DNA Methylation Alterations. DNA methylation occurs
by covalent addition of a methyl group from the methyl
donor S-adenosylmethionine (SAM) to the 5  carbon of the
cytosine ring in CpG pairs. Throughout the genome CpG
is often found clustered in particular regions called CpG
islands. CpG islands are typically methylated in silenced
genes and hypomethylated in the regulatory areas of tran-
scriptionally active genes. DNA methyl addition is carried
out by at least ﬁve DNA methyl transferases (DNMT1,
DNMT3a, DNMT3b, DNMT3L, and DNMT2). DNMT1
contributes to the maintenance of DNA methylation pat-
terns, while DNMT3a and -b methylate unmethylated DNA
and thus contribute to the novo methylation. DNMT2
displays weak DNA methyl transferase activity [18].
It has been shown that hydralazine and procainamide
remove the methyl group from cytosines present in CpG
islands through their interaction with DNA [23].
Procainamide and 5-azacythidine are competitive in-
hibitors of DNMT1 [24, 25], while hydralazine prevents
DNMT1 upregulation during mitosis by blocking ERK
pathway signaling at PKCdelta [26].
Patients with idiopathic lupus have changes in T cell
signaling identical to those caused by hydralazine. In fact it
has been demonstrated that T cells from patients with active
lupus have hypomethylated DNA, due to decreased DNMT1
levels and activity [27, 28]. Interestingly, the decrease in
DNMT1 levels is due to impaired ERK pathway signaling
caused by a block at PKCdelta, also inhibited by hydralazine
[26].
Candidate gene studies have revealed several pathways in
which aberrant gene expression due to DNA demethylation
is linked with the development of SLE. These genes include
the ITGAL (also known as CD11A) [29], which is important
for cell-cell adhesion, CD70 (encoding CD70), (also known
as tumor necrosis factor ligand super family member 7) [30],
which is required for T cell proliferation, clonal expansion,
and the promotion of eﬀector T cell formation, and CD40LG
(encoding for CD40 ligand) [31], which stimulates B cell IgG
overproduction. Other factors, such as the gene encoding
perforin 1 (PRF1), [32] which contributes to autoreactive
killing of macrophages and release of apoptotic material, are
also hypomethylated in CD4+ T cells from individuals with
SLE.
In 2009, Garaud and colleagues [33] reported that the
E1B promoter of CD5 is hypomethylated in resting SLE B
cells. This study also showed that high levels of interleukin
6 in SLE B cells, which is known to be positively associated
with SLE disease activity, reduce the expression of DNMT1.Clinical and Developmental Immunology 3
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Figure 1: Epigenetics alterations in SLE and potential pathogenic contributions to inﬂammation, CVD, and autoimmunity. See the text for
further details.
CD4 CD4
Antigen
Epigenetic alterations in RA
DNA-
alterations
miRNA
expression
Hypomethylated
DNA in:
IL17
Altered key immunomodulatory proteins
in inﬂammation and CVD
IL-6 gene
miR-146
miR-155
CD8
CD14
[35]
TNFα,
[50, 51]
methylation
Dysregulated
Figure 2: Epigenetic alterations in RA and potential pathogenic
contributions to inﬂammation and CVD. See the text for further
details.
Defective DNA methylation was also described in RA. T
cell DNA is demethylated in RA [34] and may result in the
generation of auto reactive T and/or B cell clones in RA as
it does in lupus. The CD21 promoter is also demethylated
in RA PBMC and synovial ﬂuid cells. IL-6 has been further
shown to be hypomethylated in PBMCs from individuals
with RA [35]. However, further analysis of isolated B cells
is necessary to conﬁrm whether deregulated IL-6 expression
occursinthesecellsasaconsequenceofepigeneticchangesin
RA. Nevertheless, altered methylation of IL6 in RA reinforces
the notion of the importance of applying epigenetic studies
to the investigation of pathways that are aﬀected in AIDs.
In pSS, recent studies have focused on analyzing DNA
methylation alterations in mechanotransduction and hem-
idesmosome (HD) organization-mediated mechanisms.
Changes in cell behaviour depend on mechanical signals
received by the cell from the environment (mechanotrans-
duction) [36, 37]. Experimental evidence suggests that
a physical continuum directly connects the extracellular
matrix (ECM) to the cellular nucleus [37]. Recent studies
have investigated the role of these new mechanisms in the
pathogenesis of SS and, speciﬁcally, the role of epigenetic
processes in the development of glandular damage. An
example of a mechanotransduction-mediated mechanism is
the production of lactotransferrin by glandular cells: high
levels of mRNA for lactotransferrin have been detected in a
cell fraction enriched in epithelial cells from salivary glands
of patients with SS, together with an altered distribution
of α6β4 integrin and an acinar cell shape [38]. Increased
transcription of the lactotransferrin gene suggests a role of
mechanotransduction-signalling pathways in the etiopatho-
genesis of SS.
Ar e c e n ts t u d yb yG o n z ´ alez et al. [39]f o u n da l t e r a t i o n s
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patients suggestive of epigenetic control. HDs are protein
complexes that mediate epithelial cell adhesion to the ECM
and are composed of an α6β4 integrin dimer that binds
to laminin, plectin, and other proteins (BP230 and BP180)
[40, 41]. The study found reduced levels of BP230 mRNA
in epithelial cells of patients with SS in comparison with
controls and, in contrast, an accumulation of BP230 on the
basal surface of acini [39]. An increased methylation index
of CpG islands might explain the reduced levels of BP230
mRNA, and the authors suggest that diﬀerential changes
in methylation of the BP230 gene promoter may explain
the up- and downregulation detected in patients with SS.
More recently, Yin and coworkers [42] evaluated whether
the epigenetic regulation of CD70 expression is abnormal
in pSS. They found that CD70 expression was signiﬁcantly
elevated and correlated with a decrease in TNFSF7 pro-
moter methylation in pSS CD4(+) T cells compared to
controls.
This study indicated that, as for SLE, demethylation of
theCD70promoterregulatoryelementscontributestoCD70
over expression in pSS CD4(+) T cells and may further
contribute to auto reactivity.
2.3. MicroRNAs in Autoimmune Diseases. miRNAs are short
(approximately 22 nucleotides in length) molecules of RNA
that are transcribed from noncoding regions of the genome
and exhibit signiﬁcant secondary structure [43].
The biosynthesis of miRNAs is mediated by the nucleases
Drosha, Pasha, and Dicer, involved in processing the miRNA
from a hairpin conﬁguration into a short RNA duplex
and ﬁnally into a single-stranded miRNA, which is then
loaded into the mRNA-induced silencing complex (RISC).
The RISC and associated miRNA then bind complemen-
tary sequences in 3  untranslated regions (base pairing
of microRNA nucleotides 2–8, termed seed sequence) of
mRNA species and inhibit their translation by two distinct
mechanisms: degradation of the message by the RISC
protein argonaute and prevention of ribosomal binding and
translation initiation [43].
miRNAs play a key role in biological processes, such as
embryogenesis,diﬀerentiationandproliferationofcells,pro-
duction of cytokines, and apoptosis. More than 700 miRNAs
havebeenidentiﬁedinmammaliancells,anduptoone-third
ofallprotein-encodinggenesareestimatedtoberegulatedby
these small molecules [44].
miRNA expression is tightly regulated during hemato-
poiesis and lymphoid cell diﬀerentiation, and disruption of
the entire miRNA network of selected miRNAs may lead
to dysregulated immune responses. In fact, abnormalities
in miRNA expression related to inﬂammatory cytokines,
T h - 1 7 ,a n dr e g u l a t o r yTc e l l sa sw e l la sBc e l l sh a v eb e e n
described in several AIDs [45].
In addition, it has been shown that miRNAs are present
in human plasma in a stable form. Moreover, other body
ﬂuids such as synovial ﬂuids contain measurable miRNAs
[46]. Thus, synovial ﬂuid and plasma miRNAs have addi-
tional potential as diagnostic biomarkers for some AIDs as
well as a tool for the analysis of their pathogenesis.
2.3.1. MicroRNAs in Rheumatoid Arthritis. The expression
levels of several miRNAs in PBMCs have been found
associated with inﬂammation and cytokine production, and
some of them correlated with RA disease activity [47].
In reports from diﬀerent research groups, miR-146a and
miR155 have been consistently found to be up regulated in
synovial ﬁbroblasts (RASFs), PBMCs, synovial ﬂuid, PBMC-
derived CD4+ T cells, and Th-17 cells from patients with
RA when compared with healthy controls or patients with
osteoarthritis (OA) [40, 48–51].
The study of the by Li and colleagues [50]o ft h e
expression proﬁle of miRNAs in CD4+ T cells from synovial
ﬂuid and peripheral blood of 33 RA patients showed that
miR-146a expression was signiﬁcantly up regulated, while
miR-363 and miR-498 were down regulated in RA patients.
Moreover, the level or miR-146a expression was positively
correlatedwithlevelsoftumornecrosisfactor-alpha(TNFα).
In addition, miR-146a overexpression was found to suppress
T cell apoptosis, thus indicating a role for miR-46a in RA
pathogenesis.
As a proof of the additional involvement of miR-146a
in inﬂammation and cytokine production, Niimoto and
coworkers [51] recently found that the expression of miR-
146a was associated with IL-17 expression in the PBMC and
synoviuminRApatientsandthattheincreasedexpressionof
both molecules correlated with disease activity.
A parallel survey further demonstrated that a polymor-
phism in the 3 -UTR of interleukin-1 receptor-associated
kinase (IRAK1), a target gene of miR-146a, is associated with
RA susceptibility [52].
Simultaneous investigations in PBMCs from acute
coronary syndrome patients further showed signiﬁcantly
increased expression of miR-146a [53]. Moreover, the over
expression of miR-146a was found to signiﬁcantly unreg-
ulate the function of Th1 cells. This study also provided
evidence that miR-146a treatment in vitro could induce
the protein expression of TNFα, MCP-1 and NFκB p65,
which are, respectively, key proinﬂammatory cytokines and
critical transcription factor in atherosclerosis. Although
further detailed studies are required, these results support
the hypothesis that miR-146a may be directly involved
in the pathogenesis of CVD associated to AIDs such as
RA.
2.3.2. miRNAs in Systemic Lupus Erythematosus and Anti-
phospholipid Syndrome. The ﬁrst study reported about
miRNA expression in PBMCs from SLE was the study by
Dai and coworkers [54], performed in 23 SLE patients and
10 healthy controls. In those SLE patients, 7 miRNAs (miR-
196a, miR-17-5p, miR-409-3p, miR-141, miR-383, miR-112,
andmiR-184)weredownregulatedand9miRNAs(miR-189,
miR-61,miR-78,miR-21,miR-142-3p,miR-342,miR299-3p,
miR-198, and miR-298) were up-regulated as compared with
healthycontrols.However,thatstudydidnot providefurther
data to show how these changes in miRNA may play a role in
SLE disease pathogenesis.
A recent study has shown the involvement of miR-125a
in the inﬂammatory chemokine pathway in SLE [55]. InClinical and Developmental Immunology 5
SLE patients, the expression of miR-125a was found to be
reduced, and the expression of its predicted target gene,
KLF13, was increased. This study also showed that miR-125a
negatively regulated RANTES expression by targeting KLF13
in activated T cells.
It has also been recently demonstrated the down regula-
tion of miR146 in PBMCs from SLE patients, as well as its
involvement in IFN over expression [56].
APS and SLE are two conditions known to provoke
increased tissue factor (TF) expression in monocytes and
endothelial cells [57–61]. In a recent study by our group,
we checked in patients with APS or SLE the hypothesis that
miRNA levels may inﬂuence TF levels in those patients.
Thus we measured by RT-PCR the levels of miR-19b and
miR-20a (reported to targeting TF expression in several
web databases and algorithms of miRNA target prediction)
in monocytes from APS and SLE patients. In APS we
found that the levels of these two miRNAs had an approx-
imate 3-4-fold decrease in comparison with monocytes
from healthy controls. In monocytes from SLE, miR-20a
levels were also lower than those from healthy subjects
(3-fold decrease). In addition, the reduced expression of
miR-19b and miR-20a was inversely correlated with TF
cell surface expression [62]. These results shed light on
new mechanisms that may regulate the expression of TF
and thus the occurrence of thrombotic events in these
AIDs.
2.3.3. miRNAs in Primary Sj¨ ogren Syndrome. Studies on
the role of microRNAs (miRNAs) in the pathogenesis
of pSS have centred on analysing miRNAs from salivary
exosomes. Exosomes are small cellular vesicles (30–100nm)
that contain a wide range of surface and internal proteins
speciﬁc to their cellular origin [63], and recent studies have
shown that exosomes can also transport mRNA and miRNA
[64, 65]. Alevizos et al [66] tested the potential of salivary
glandmiRNAsasabiomarkerofSS,usingAgilentmicroRNA
microarrays to proﬁle miRNAs isolated from the salivary
glands of healthy controls (n = 8) and patients with SS, who
were classiﬁed according to a high focus (n = 8) or low focus
score (n = 8). MicroRNA expression patterns distinguished
salivary glands from control subjects and the two groups of
patients with SS. The authors identiﬁed two miRNAs (768-
3p and 574) which were inversely correlated with the focus
score. In addition, they found down-regulation of the mir-
17-92 cluster in half the SS patients with a high focus score.
Previous studies have associated down-regulation of the mir-
17-92 cluster with an accumulation in pro-B cells and a
marked reduction of pre-B cells, which has been associated
with lymphoproliferative and autoimmune diseases [67, 68].
Larger studies are currently underway to validate miRNAs
from salivary glands as diagnostic markers in SS [69].
Moreover, parallel analyses on PBMCs from both mice and
human are currently underway so that Lu and co-workers
[70]havepresentedpreliminarydatadescribingtwomiRNAs
(150and146)thatareupregulatedinboth,targettissuesand
in PBMCs of the B6DC mice, and in PBMCs and salivary
glands of SS patients.
3.Epigenetic Alterations,
Inﬂammation,andCardiovascular
Involvement in Autoimmune Diseases
Signiﬁcant evidence has shown that there is heterogeneity
in the characteristics of vasculopathies underlying diﬀerent
autoimmune diseases such as APS, SLE, RA, and pSS. It has
been also shown a relevant heterogeneity with respect to
inﬂammatoryriskfactors.Thedatapresentedinthisrevision
further indicated that epigenetic mechanisms also seem to
inﬂuence inﬂammation and cardiovascular disease in those
autoimmune conditions.
In SLE, relevant factors directly inﬂuencing the develop-
mentofCVDandATcompriseimmunecomplexgeneration,
complement activation, and changes in the production and
activity of a complex network of cytokines, including type I
and II interferons, B lymphocyte stimulator (BLyS), TNFα,
IL-6, IL-17, and migration macrophage inhibitor (MIF) [71–
82]. Epigenetic analyses have demonstrated aberrant gene
expression due to DNA methylation linked to both, the
development of the disease and to inﬂammation and AT
(such as ITGAL, CD70, and CD40L) [28–30]. There have
been also found signiﬁcant clusters of aberrantly expressed
genes in SLE (codifying for a set of chemokines) strongly
associated with altered H4 acetylation [22]. Concerning
altered miRNA expression, various studies have demon-
strated in PBMCs altered expression of some miRNAs
(miR-125a and miR-146) involved in the regulation of
inﬂammatory chemokine pathways as well as of IFN over
expression [54, 55].
In Antiphospholipid Syndrome (APS), an autoimmune
disease in which thrombosis development constitutes a
major pathological feature, procoagulant cell activation,
accompanied with TF expression and TF pathway up reg-
ulation, is one of the key events considered explaining the
prothrombotic tendency [57–61]. Although this pathology
has been also associated with inﬂammatory condition and
early AT development, no epigenetic studies have been
developed to date to prove any relationship with those
pathogenic processes. Nevertheless, along with SLE, the
over expression of TF has been demonstrated in APS to
be accompanied with an epigenetic change: the altered
expression of miR-19b and miR-20a [62]. Although more
deep studies are required, this association reveals a new
mechanism involved in the pathophysiology of thrombosis
in both autoimmune diseases.
In RA, pathogenic mechanisms involved in CVD and
AT development include prooxidative dyslipidemia, insulin
resistance, prothrombotic state, and immune mechanisms
such as T cell activation that subsequently leads to endothe-
lial dysfunction and arterial stiﬀness [83, 84]. Anticyclic
citrullinated peptide antibodies (anti-CCP), IgM rheuma-
toidfactor,circulatingimmunecomplexes,proinﬂammatory
cytokinesincludingTNFαandIL-6,Th0/Th1cells,decreased
folate and vitamin B12 productions, and impaired paraox-
onase activity, among others, may all be further involved
in the development of vascular disease in RA [85–87].
Epigenetic data indicate that defective DNA methylation6 Clinical and Developmental Immunology
might also be relevant to CVD and AT development in RA,
so that it has been shown hypomethylation of IL-6 promoter
[35]. Furthermore, the expression levels of some miRNAs in
PBMCs have been found associated with inﬂammation and
cytokine production, including the over expression of miR-
146a (which positively correlated with levels of TNFα and
IL-17) [50, 51].
In primary SS, various studies concluded that there is
evidence that those patients have both early subclinical AT
and altered lipid proﬁle with potential AT risk. In that
pathology, the key role in determining the acceleration of
AT seems to be played by immune-mediated mechanisms.
Numerous interferon regulatory genes have been also found
to be highly expressed in T cells and in salivary gland tissue
[14–17].
Concerning epigenetic studies suggesting inﬂammation
and CVD involvement in SS, to date only one group have
reached concluding results. The study group of Cha and co-
workers has developed non obese diabetic mice (B6DC) that
develop a disease similar to human SS. They have described
two miRNAS (150 and 146) that are up regulated in target
tissuesandinPBMCsoftheB6DCmicecomparedtocontrol
mice. That group further reported that miR-146 expression
isincreasedinPBMCsandsalivaryglandsofSSpatients[70],
whichmightberelatedtoIFNproduction.Hypomethylation
and over expression of CD70 (TNFSF7) in CD4+ T cells
of patients with primary Sj¨ o g r e n ’ ss y n d r o m eh a v eb e e na l s o
demonstrated [42]. Although the studies delineating the
precise role of epigenetic alterations in inﬂammation and/or
CVD in SS are just beginning, preliminary data suggest that
pSS may represent an interesting model to study the factors
involved in early development of AT.
4. miRNA Common to Different Autoimmune
Diseases But Controlling Distinct Inﬂamma-
toryProﬁles: The Master Role of miR-146a
miR-146 and miR-155 have been shown to be induced by
proinﬂammatory stimuli such as IL-1, TNFα, and Toll-like
receptors (TLRs) [88]. They have also been detected in
synovial ﬁbroblasts, and rheumatoid PBMCs and synovial
tissue, as well as in regulatory T cells serum, and urine cell
free samples from SLE patients [89]. Both miRNAs have
multiple targets, with miR-146 inhibiting TLR signalling
and miR-155 regulating Th1 cells and also, interestingly,
positively regulating mRNA for TNFα.
Concomitantly, Tang et al. [56] have shown that miR-146
regulatesthelevelofatleastTRAF6,IRAK1,STAT-1,andIFN
regulatoryfactor5(IRF-5),allofwhichareimportantforthe
IFN pathway. The reported reduction of miR146 in PBMCs
from SLE patients will likely aﬀect the levels of these factors
signiﬁcantly and contribute to over expression of type I IFN
and, in turn to disease activity.
Independent studies have demonstrated an increased
level of miR146 in RA patients, but a decreased level in SLE
patients, as compared with healthy controls. Given that RA
and SLE are both systemic rheumatic diseases, one may be
surprised by the ﬁnding that miR-146 levels are opposite
in these diseases. Yet, as suggested by Chan et al. [90], this
maysimplyreﬂectadiﬀerenceintheoverallcytokineproﬁles
betweenthetwodiseases,withtypeIIFNplayingadominant
role in SLE, whereas TNFα, interleukin-1, and IL-6 are the
main cytokines in RA. That data reinforce the idea of the
existence of some miRNAs as master gene regulators in
diﬀerent autoimmune diseases.
5. Control of DNA Methylation viamiRNAs
Only recent studies have suggested that miRNAs can reg-
ulate DNA methylation by targeting the DNA methylation
machinery in SLE. Pan et al. [91] identiﬁed 2 miRNAs,
miR-21 and miR-148a, as being up-regulated in CD4+ T
cells in both patients with lupus and MRL/lpr mice, an
animal model of lupus. Moreover, both miRNAs down
regulate the protein levels of DNMT1, thus resulting in
hypomethylation status in CD4+ T cells. In particular,
miR-21 indirectly down-regulates DNMT1 by targeting its
upstream regulator, Ras guanyl-releasing protein 1, while
miR-148a directly down regulates DNMT1 by targeting the
protein-coding region of its transcript. The ﬁnal result is
the derepression of autoimmune-associated methylation-
sensitive genes in CD4+ T cells, such as CD70 and lympho-
cyte function-associated antigen 1 (LFA-1; CD11a). These
investigatorswerealsoabletoinducethepotentialalleviation
ofhypomethylationinCD4+Tcellsfrompatientswithlupus
by transfection with miR-21 and miR-148a inhibitors.
The study by Zhao et al. [92] further expanded the role
of miRNAs and epigenetic changes in SLE. The novel ﬁnding
was that, among the 11 microRNA that were observed to
have increased or decreased expression in CD4+ T cells
from patients with SLE, miR-126 was signiﬁcantly over
expressed,anditsup-regulationwasinverselycorrelatedwith
DNMT1 protein levels. Zhao and colleagues were then able
to demonstrate that miR-126 can directly inhibit DNMT1
translation by interacting with its 3 -UTR, leading to a
signiﬁcant reduction in DNMT1 protein levels. Through this
mechanism, over expression of miR-126 causes demethyla-
tionandup-regulationofgenesencoding forLFA-1(CD11a)
and CD70, two autoimmune-related proteins, which are
directly proportional to disease activity. The miR-126 host
gene EGFL7 was also over expressed in SLE CD4+ T cells, in
a hypomethylation-dependent manner.
TheywerealsoabletoshowthatknockingdownmiR-126
in SLE CD4+ T cells reduced their autoimmune activity and
their stimulatory eﬀect on IgG production in the cocultured
B cells.
6. Therapeutic Potential of Epigenetic
Modiﬁcations inAutoimmune Diseases
Unlike genetic alterations, which are permanent, epigenetic
alterations are reversible. This opens up the possibility of
using epigenetic drugs to reverse the pattern of epige-
netic alterations to relieve the phenotype. To date, HDAC
inhibitors such as suberoylanilide hydroxamic acid and
trichostatin A (TSA) have proved to be useful for relievingClinical and Developmental Immunology 7
lupus disease in mice [93]. The eﬀects of TSA on human T
cellsarepredominantlyimmunosuppressiveandreminiscent
of the signaling aberrations that have been described in
patients with SLE.
Inhibition of HDACs has also been shown to alleviate
renal disease in a mouse model of SLE [94, 95]. In line with
this, it has been recently reported that HDAC inhibition is
eﬃcient in the treatment of juvenile idiopathic arthritis [96].
In autoimmune diseases, inhibiting DNA methylation
would not be appropriate to revert DNA methylation
changes, as the changes identiﬁed to date are hypomethyla-
tion, not hypermethylation; thus, agents should be designed
to speciﬁcally increase methylation, and no such speciﬁc
methylating agent exists. Nevertheless gene-gene speciﬁc
hypermethylation cannot be ruled out [93].
Furthermore, DNA demethylating agents such as hydra-
lazine have been shown to subvert B lymphocyte tolerance
and to contribute to the generation of pathogenic auto
reactivity [97].
It is not clear whether the increased expression of speciﬁc
miRNAsisanindirecteﬀectratherthanthecauseofSLE,and
this point also needs further investigation in future studies.
The hypothesis that many miRNAs are master regulators of
gene expression remains attractive to select interesting target
miRNAs for the development of new therapeutics.
7. Conclusions
There is a wealth of emerging evidence showing that
epigenetics processes are involved in promoting autoimmu-
nity. Yet, it remains unclear whether epigenetic changes in
autoimmune diseases are causally related to the pathogenetic
features, such as immune responses or inﬂammatory status,
or whether they merely represent a consequence of the
ongoing pathological process. However, epigenetic changes
could at least partly explain poorly understood environ-
mental eﬀects on disease development and the enhanced
cardiovascular risk observed in AIDs.
Epigenetic alterations can be used as clinical markers
of disease progression or response to therapy. As stated
above, hypomethylation, although very relevant to the
pathology of the autoimmune disease, cannot be considered
as a biomarker for development of alternative therapies.
However, the current studies have indicated a huge potential
of using miRNAs as gene therapy targets in vivo to treat
cancer. In the same way, it can be anticipated that in the
near future novel eﬀective miRNA-based gene therapies will
be developed to replace the traditional immune-suppressive
therapies to treat autoimmune diseases.
Identiﬁcation of novel epigenetic targets, a better under-
standing of the epigenetic mechanisms involved in car-
diovascular disease, and development of novel compounds
directed against them will surely open up novel therapeutic
approaches in systemic autoimmune diseases.
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